Research dossier
AOD-9604 — hGH(176-191) fragment dossier
A growth hormone fragment stripped of its receptor-binding domain.
Translated from the French original, which remains the reference version: lire en français →
Molecular identity
| Parameter | Value |
|---|---|
| CAS number | 221231-10-3 |
| Molar mass | 1815.05 g/mol |
| Molecular formula | C₇₈H₁₂₃N₂₃O₂₃S₂ |
| Sequence / nature | Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (HGH 177-191) |
| Purity | ≥99% |
| Appearance | White lyophilised powder |
The values above correspond to the catalogue lot and are reproduced as they stand from the product page. Any discrepancy between this dossier and the product page should be reported before use.
Research context
This fragment illustrates an attempt at functional dissociation: separating a metabolic activity from a growth activity carried by the same protein. That the mechanism remains unelucidated is part of what makes the case interesting — it documents how difficult that approach is.
Mechanism studied
AOD-9604 corresponds to the C-terminal 176-191 fragment of human growth hormone, with an added N-terminal tyrosine.
The decisive point is structural: this fragment does not carry the domains of the whole protein responsible for binding to the growth hormone receptor. It therefore cannot activate that receptor, and the literature is explicit on this point — the reported effects, if they exist, do not run through the classical GHR/JAK2/STAT5 pathway.
That dissociation is precisely what motivated study of the fragment: identifying a metabolic activity separable from the growth activity. The published in-vitro work deals with adipocytes in culture, measuring lipolysis by assaying the glycerol released into the supernatant, and with hormone-sensitive lipase expression.
The precise molecular mechanism remains poorly established, however: no specific receptor has been identified for this fragment, which is an acknowledged limit of the literature.
In-vitro literature
The models used are mostly differentiated 3T3-L1 adipocytes. Results vary appreciably with the differentiation protocol, a known source of inter-laboratory variability.
Bibliographic entry points
- PubMed — peer-reviewed literature
- PubChem — chemical profile and assay data
- NCBI — methodology and receptor references
These links are an entry point into the literature, not an edited selection. None of the sources cited relates to a human use of this material, and consulting them directly is recommended for any protocol design.
Distinguishing this compound from its analogues
A fragment lacking the growth hormone receptor-binding domains: data on whole hGH are not transposable to it.
The CAS number shown on the product page is the identifier to rely on. Trade names, development codes and customary abbreviations vary from one source to another and are not a reliable identification.
Methodological limits
The absence of an identified receptor for the fragment is the central limit: effects reported in culture cannot be tied to a defined signalling pathway. The differentiated adipocyte models also show substantial inter-laboratory variability linked to the differentiation protocol.
These limits are not formalities: they determine what a protocol using this material can and cannot establish. Making them explicit in the experimental plan avoids attributing to the compound an observation that belongs to the measurement system.
Analytical parameters
A 16-residue fragment carrying a disulfide bridge. The integrity of the ring must be verified, since the reduced form does not have the same conformation.
| Parameter | Value |
|---|---|
| Storage | Store at −20 °C, protected from light |
| Solubility | Soluble in bacteriostatic water (BAC) |
| Stability | Stable for 24 months at −20 °C; 30 days after reconstitution at 2–8 °C |
| Control methods | RP-HPLC · MS · NMR |
Reconstitution is a matter for the experimental protocol. The volume of solvent determines the final concentration and is not prescribed here: it depends on the design of the experiment and the conditions of the assay.
Resulting concentrations
The table below is arithmetic: it gives the concentration obtained for a given solvent volume, with no recommendation of use.
| Format | 1 ml | 2 ml | 3 ml |
|---|---|---|---|
| 10mg | 10.00 mg/ml | 5.00 mg/ml | 3.33 mg/ml |
These values assume complete dissolution and a peptide content consistent with the lot report. Where the actual quantitative content differs from the nominal mass — a common discrepancy, caused by counter-ions and residual water — the effective concentration is lower than the theoretical value. That is precisely why quantitative content per vial forms part of the verification protocol.
Protocol design
Three points govern the validity of an assay using this material, whatever the question being asked.
The effective concentration is not the nominal concentration. It depends on the actual peptide content of the lot, on complete dissolution and on adsorption to the walls of the container. A concentration check after reconstitution is preferable to assuming a perfect yield.
The actual exposure time may be shorter than the nominal duration where the compound is degraded by the medium. Verify stability under the exact conditions of the assay — medium, serum, temperature, duration — before interpreting an absence of effect.
The control arm must correspond to the vehicle actually used, at the same final concentration. This requirement is unremarkable and remains the most frequent cause of irreproducible results.
Lot verification
The following formats are covered by a Janoshik Analytical report, readable from the product page:
- 10mg — lot report available
| Format | Lot report | Availability |
|---|---|---|
| 10mg | Covered | In stock |
The verification programme covers exclusively the identity and purity of the material, by reversed-phase chromatography and mass spectrometry. It covers neither sterility, nor endotoxins, nor any microbiological characteristic.
Frequently asked questions
How does this product arrive?
As a lyophilised powder in a sealed vial, shipped in insulated, plain packaging. Return the vial to the storage temperature given in the specifications on receipt.
Which solvent should be used for reconstitution?
Bacteriostatic water is the usual reconstitution solvent for lyophilised peptides in a laboratory setting. The volume is a matter for the experimental protocol and the concentration sought; we provide no dosage recommendation.
How long does the material remain stable?
The stability window appears in the specifications table on this page, before and after reconstitution. Those values correspond to the storage conditions stated; any temperature variation shortens them.
Does the analysis report correspond exactly to my vial?
The report linked on this page corresponds to the format selected. Each report is issued by Janoshik Analytical from an anonymously submitted sample, and covers the identity and purity of the peptide.
Can this product be used on humans or animals?
No. It is an analytical grade reference material intended exclusively for in-vitro laboratory research. Any administration to humans or animals is excluded, and no therapeutic, diagnostic or medical claim is made.
Dossiers in the same category
- SLU-PP-332 — CAS 303760-60-3